(1) Biologics have had a tremendous impact on the management of rheumatoid arthritis.(2) Three new biologics have been approved or filed for approval for the treatment of rheumatoid arthritis in the last 2 years: abatacept, rituximab, and tocilizumab.(3) The utility of the newer biologics against the background of existing, well established biologics (infliximab, etanercept, adalimumab, and anakinra) has not been evaluated systematically.
No takes yet. Share an insight, caveat, or question.
M Asif A Siddiqui (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: